Clinical Research Division, Fred Hutch
Dr. Heather Cheng focuses on improving the care of patients with prostate and bladder cancers. An expert in prostate cancer genetics, she is studying ways to use genetics to guide the care of prostate cancer patients and their family members who may also be at high risk for the disease. Dr. Cheng leads clinical trials of a variety of new treatments for prostate cancer. She is also developing new tests that could help guide doctors’ choice of treatment for each patient and new blood tests to detect and monitor the progression of prostate cancer.
Division of Medical Oncology, Department of Medicine, University of Washington
University of Washington, Program in Molecular and Cellular Biology, 2005, (Ph.D.)
University of Washington, School of Medicine, 2007, (M.D.)
University of Washington, Internal Medicine Residency, 2007-2009
University of Washington, Hematology/Oncology Fellowship, 2009-2013
Tumor and inherited genetics of prostate cancer
Novel therapeutics in prostate cancer
Correlative science/translational studies in clinical trials
Clinical and molecular predictors of response to cancer therapies
A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and
Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer
Monotherapy in Subjects with Metastatic Urothelial Cancer that Express Nectin-4
Prostate Cancer Predisposition and Inherited Cancer Risk
Clinical Trials and Experimental Therapeutics
Bladder Cancer and Testicular Cancer
Study Number: 9381
Study Number: 9831
Study Number: 9841
Study Number: 20162044
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210.